home / stock / tara / tara quote
Last: | $3.09 |
---|---|
Change Percent: | 0.27% |
Open: | $3.73 |
Close: | $3.09 |
High: | $3.74 |
Low: | $2.95 |
Volume: | 797,808 |
Last Trade Date Time: | 05/17/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$3.09 | $3.73 | $3.09 | $3.74 | $2.95 | 797,808 | 05-17-2024 |
$3.74 | $3.73 | $3.74 | $3.87 | $3.52 | 547,290 | 05-16-2024 |
$3.71 | $3.43 | $3.71 | $3.79 | $3.32 | 1,300,255 | 05-15-2024 |
$3.34 | $3.21 | $3.34 | $3.57 | $3.21 | 937,415 | 05-14-2024 |
$3.24 | $3.02 | $3.24 | $3.35 | $2.97 | 630,832 | 05-13-2024 |
$3 | $3.19 | $3 | $3.3399 | $2.87 | 922,419 | 05-10-2024 |
$2.98 | $2.81 | $2.98 | $3.25 | $2.81 | 954,990 | 05-09-2024 |
$2.83 | $2.89 | $2.83 | $2.95 | $2.8 | 155,266 | 05-08-2024 |
$2.87 | $2.93 | $2.87 | $3 | $2.87 | 80,072 | 05-07-2024 |
$2.9 | $2.88 | $2.9 | $3.03 | $2.88 | 109,132 | 05-06-2024 |
$2.91 | $2.91 | $2.91 | $2.99 | $2.835 | 134,386 | 05-03-2024 |
$2.89 | $2.96 | $2.89 | $3 | $2.85 | 118,568 | 05-02-2024 |
$2.93 | $2.98 | $2.93 | $3.2 | $2.87 | 250,728 | 05-01-2024 |
$2.98 | $3.06 | $2.98 | $3.1099 | $2.84 | 281,550 | 04-30-2024 |
$3.1 | $2.92 | $3.1 | $3.16 | $2.86 | 782,881 | 04-29-2024 |
$2.925 | $3.16 | $2.925 | $3.23 | $2.83 | 255,029 | 04-26-2024 |
$3.05 | $2.8 | $3.05 | $3.05 | $2.75 | 263,460 | 04-25-2024 |
$2.82 | $3.01 | $2.82 | $3.11 | $2.8 | 422,081 | 04-24-2024 |
$3 | $3.04 | $3 | $3.1813 | $2.82 | 411,609 | 04-23-2024 |
$3.05 | $3.08 | $3.05 | $3.35 | $2.89 | 536,534 | 04-22-2024 |
News, Short Squeeze, Breakout and More Instantly...
ArTara Therapeutics Inc. Company Name:
TARA Stock Symbol:
NASDAQ Market:
Reported positive data from three-month evaluable CIS patients treated across ongoing TARA-002 clinical program in NMIBC Preliminary data from six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC expected in 2H 2024 Reached alignment with FDA on registrational p...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
Friday, Protara Therapeutics Inc (NASDAQ:TARA) shared data from three-month evaluable carcinoma in situ (CIS) patients treated across TAR...